Interestingly, in vitro modeling of acquired resistance to RAF/EGFR or RAF/MEK in BRAF-mutant CRC cells revealed that resistant lines had acquired activating mutations in KRAS, supporting the notion that KRAS activation can drive resistance to these therapies. Here, BRAF is linked to colorectal carcinoma.